HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis.

Abstract
Neutrophilic eccrine hidradenitis has been described in patients with acute myelogenous leukemia and other malignant diseases, usually during chemotherapy. We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine. Dapsone, 100 mg daily, was initiated 48 hours before the patient's third treatment with lomustine and was continued for 14 days. This regimen was successful in suppressing the reaction during the first course and three subsequent courses of lomustine.
AuthorsN H Shear, S R Knowles, L Shapiro, P Poldre
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 35 Issue 5 Pt 2 Pg. 819-22 (Nov 1996) ISSN: 0190-9622 [Print] United States
PMID8912594 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Lomustine
  • Dapsone
Topics
  • Antineoplastic Agents (adverse effects)
  • Dapsone (therapeutic use)
  • Hidradenitis (chemically induced, drug therapy)
  • Hodgkin Disease (drug therapy)
  • Humans
  • Lomustine (adverse effects)
  • Male
  • Middle Aged
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: